William Russell
Wilmington, NCNPI 1689674954
Payments from drug & device makers
$3,149in general payments, 2019–2025
Across 171 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$580
- Johnson & Johnson$531
- Dendreon Pharmaceuticals LLC$315
- Pfizer$245
- 180 Medical, Inc.$214
- Endo Pharmaceuticals Inc.$158
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,90692%
- Education$2438%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
21
22
23
24
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 30 | $580 |
| Johnson & Johnson | 26 | $531 |
| Dendreon Pharmaceuticals LLC | 16 | $315 |
| Pfizer | 14 | $245 |
| 180 Medical, Inc. | 12 | $214 |
| Endo Pharmaceuticals Inc. | 10 | $158 |
| Blue Earth Diagnostics | 6 | $123 |
| AbbVie(2 entities) | 7 | $111 |
| Amgen | 5 | $98 |
| Coloplast | 6 | $94 |
| Myovant Sciences Inc. | 5 | $91 |
| Boston Scientific | 4 | $82 |
| Acerus Pharmaceuticals Corporation | 3 | $70 |
| Merck | 3 | $50 |
| Hollister Incorporated | 3 | $46 |
| Palette Life Sciences, Inc. | 1 | $38 |
| Urovant Sciences Inc | 2 | $33 |
| Smith+Nephew | 2 | $30 |
| Urogen Pharma, Inc. | 2 | $25 |
| Zyla Life Sciences, Inc. | 2 | $25 |
| Bayer | 2 | $25 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 2 | $23 |
| Novartis | 1 | $22 |
| Medtronic | 1 | $21 |
| Convatec Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 12 | $12,437 |
| JardianceEmpagliflozin | 13 | $7,885 |
| Metformin Hcl ErMetformin Hcl | 13 | $374 |
| Atorvastatin Calcium | 13 | $203 |
| Lisinopril | 13 | $161 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.